Monash IVF Shares Fall After Rejecting Takeover Offer

MONASH IVF GROUP LTD has rejected a second takeover proposal from a consortium, leading to a significant drop in its share price. The bid, which valued the fertility services provider at A$350.7 million ($250.36 million), was dismissed by the board on the grounds that it significantly undervalued the firm's market position in Australia.

The consortium, which includes Genesis Capital and the investment arm of WASHINGTON H SOUL PATTINSON, proposed a price of A$0.90 per share. This offer represented a premium over recent trading prices but was deemed insufficient by the board when compared to similar transactions within the domestic IVF sector. This marks the second time the group has turned down the consortium, following the rejection of a A$311.7 million offer in November.

Following the announcement on Monday, shares of Monash IVF plummeted by as much as 11.1%, reversing the majority of the gains seen since the revised offer was first made public on April 13. The stock had previously closed at A$0.765 on Friday. Chairman Richard Davis explained the decision in an official statement regarding the valuation.

The Board, in consultation with its advisers, has formed the view that the revised proposal in its current form undervalues the company.

Despite the rejection, Monash IVF indicated that it remains open to considering higher offers that more accurately reflect its intrinsic value and growth prospects within the healthcare market.